Seattle drug firm ZymoGenetics has taken Bristol-Myers Squibb (BMS)
to court for infringement of its fusion protein technology patents
by several products, including arthritis medication Orencia
Spurred on by the frustration of drug manufacturers, governors from
four US states have petitioned the US Food and Drug Administration
(FDA) for clarity in their requirements for the production of
generic versions of insulin and human...
In an incident that state and federal environmental regulators are
treating as "serious," Merck released 25 gallons of a
cyanide-containing chemical from its West Point facility in
Pennsylvania to the sewer, killing hundreds...
Life sciences firm Cambrex has agreed a contract for the production
of clinical trial quantities of Merrimack Pharmaceuticals'
recombinant immunomodulatory serum protein, as its experience in
the downstream purification of proteins...
A new drug discovery technique, which uses mixed-mode sorbents in
process chromatography, has the potential to significantly reduce
costs and environmental burdens, especially in the protein
Swiss biopharmaceutical firm Biopartners has got the thumbs up from
the European Commission for its biosimilar drug Valtropin, making
it only the second biogeneric drug to have been approved in Europe
after Sandoz's Omnitrope...
In its second acquisition in less than a month, Millipore has
acquired bioprocessing products firm Serologicals for around $1.4bn
(€1bn) in cash, as it tries to boost its growth by expanding in
potentially lucrative market segments.
As the threat of new viruses like avian influenza have heightened
the need for greater speed and safety in vaccine production, single
use technologies are proving far more safe and economic than
traditional cleaning techniques, according...
Thanks to a £2.7m (€3.9m) access fund from the UK's National
Biomanufacturing Centre (NBC), biotech firm Onyvax has hired
contract manufacturer organisation (CMO) Eden Biodesign to supply
it with clinical current good manufacturing...
Responding to surging demand for its flu drug Tamiflu, Roche has
announced it is expanding its external contractors to fifteen in
nine different countries, as its needs for intermediates and
finished product increase.
Filtration systems specialist Pall's net profit barely moved in Q2
compared to the similar period last year, up only $400,000
(€331,328) to $32.4m, still its Biopharmaceuticals business, driven
by a steady demand in consumables,...